

LABOMAR AND NOVENTURE: MEDICAL DEVICE SECTOR PARTNERSHIP STRENGTHENED

DOUBLING SUPPLY OVER ONE YEAR FOR FORECAST REVENUES (LABOMAR) OF EURO 2.8 MILLION

Istrana (TV), July 12th, 2022 - Labomar S.p.A. (Ticker: LBM), an Italian-based international nutraceutical enterprise listed on the Euronext Growth Milan market, which specialises in the development and production of dietary supplements, medical devices, foods for special medical purposes and cosmetics for third parties, announces the consolidation of its partnership with the international enterprise Noventure, part of the Spanish-based pharmaceutical company Ferrer, and a medical device distributor and special dietary supplement specialist across Europe.


After formalising their collaborative relationship in 2016, the parties further strengthened the partnership in June 2022, with the aim of consolidating Noventure's medical device sales in Europe and beyond, including through a specific plan to comply with the new European Medical Device Regulation (MDR) that has further raised product quality and safety standards, while creating a sustainable legislative framework.

The total expected turnover from the partnership with the Spanish entity for the year 2022, for Labomar, is Euro 2.8 million.

Noventure's medical devices, predominantly focused in the gastro and urological segments, mainly target the European markets.

Walter Bertin, founder and chairperson of Labomar Group, underlined *"Strengthening our partnership with an internationally-recognised entity such as Noventure consolidates our trajectory as a cutting-edge supplier, always attentive to regulatory changes and their implications. This partnership also allows us to reach new markets by complementing Noventure's range with Labomar's supplements. We are confident that our team's efforts in this direction will increasingly bear fruit"*.

Luciano Conde, CEO of Noventure, said *"Noventure is proud of its successful relationship with Labomar to offer consumers the benefits of our range of substance-based medical devices and specialized food supplements, which are currently available in more than 45 countries. It is a privilege to build long-lasting partnerships with companies, like Labomar, that are committed to developing and marketing innovative products"*.



Noventure Profile

Noventure is a Spanish company based in Barcelona. It is specialized in licensing innovative substance-based medical devices and specialist food supplements. It markets approved medical devices under the CE Mark - ready for marketing in the EU and in territories around the world - and singular food supplements in the areas of gastroenterology, urogynecology, pediatrics and dermatology. Noventure's innovative, substance-based medical devices are patient-friendly, effective solutions. The specialized food supplements come in distinctive galenic formulations, thereby increasing acceptability and adherence, and improving consumer experience.

Labomar Profile

Founded by Walter Bertin in Istrana (province of Treviso) in 1998, Labomar is specialised in the development and production of food supplements, medical devices, foods for special medical purposes and cosmetics for third parties. Over more than 20 years, Labomar has built a business model which sets it apart from its competitors and generates value for all stakeholders, providing a comprehensive service and a high quality and productivity standard. The company boasts a well structured and cutting-edge research and development department with a particular focus on innovation, a commercial team which reacts quickly to market demands and a high level of product differentiation thanks to its proprietary patents and formulas.

Labomar reported in 2021 consolidated revenues of approx. Euro 65.4 million, up 7.1% on 2020. The 2021 figure includes, in addition to the revenues of the parent company and the Canadian Entreprises ImportFab Inc., also those for H2 of the Welcare Group and, for December alone, of Labiotre Srl. Labomar SpA's revenues in 2021 were approx. Euro 53.8 million, increasing nearly 4 percentage points on 2020.

Labomar in 2021 acquired 70% of the Welcare Group. The Group comprises Welcare Industries Spa and Welcare Research Srl, producers of medical devices for skincare, with its registered office in Orvieto. LaboVar Srl was also established - 51% owned by Labomar - for the sale of nutraceutical products on an e-commerce platform on the Chinese market. Labomar then acquired full control of Labiotre Srl, a Tuscan enterprise specialising in the production of plant extracts, fully integrating the supply chain concept advocated by the company.

Labomar sincerely believes in operating as a business centred on sustainability and the well-being of the individual, the environment and the community. It has therefore amended its By-Laws to become a Benefit company. This new legal status, introduced in Italy in 2016, formalises the decision to develop a responsible, sustainable and transparent development model, which marries operating-earnings objectives with social and environmental aspects.

For further information:

Labomar Press Office

Thanai Bernardini - +39.335.7245418 - me@thanai.it

Alessandro Bozzi Valenti - +39.348.0090866 - alessandro.valenti@thanai.it

Labomar Investor Relations

Claudio De Nadai - +39.0422.677203 - claudio.denadai@labomar.com

Mara Di Giorgio - +39 335 7737417 - mara@twin.services

Euronext Growth Advisor

Banca Mediolanum - +39 02 9049 2525 - ecm@mediolanum.it